Investigators conducted a study to determine the effects of quinine hydrochloride in combination with antimicrobial blue light therapy in patients with cutaneous mold infection.
Investigators conducted a study to determine outcomes following early de-escalation to fluconazole following echinocandin empirical treatment in patients with fluconazole-susceptible candidemia.
The FDA has accepted for filing and granted Priority Review to the NDA for ibrexafungerp (SCY-078; Scynexis) for the treatment of vulvovaginal candidiasis.
Investigators summarized the evidence on the efficacy and adverse effects of antifungal agents in patients with hematological disease or undergoing hematopoietic stem cell transplantation.
Critically ill patients hospitalized with COVID-19 — particularly those who develop ARDS — may also experience an opportunistic aspergillosis superinfection.
The FDA has approved the sNDA for Mycamine for the treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients aged <4 months.
Scynexis announced positive topline results from the phase 3 VANISH 303 trial of ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) in women.
Patients with a long-term history of type 2 diabetes mellitus (T2DM) carried Candida albicans in their dental root canals more frequently when they have a primary endodontic infection.
Multidrug-resistant Candida auris is an urgent antimicrobial resistance threat and the key method of prevention is strict adherence to infection control measures.
